Page 186 - Drug Class Review
P. 186
Page 123 of 205
Drug Effectiveness Review Project
placebo N/A 24 weeks 162
To study the efficacy and safety of DON for patients with mild to moderate AD
donepezil 10 mg/d 24 weeks 157 Men and women of any race > 50 yrs old diagnosed with uncomplicated AD; probable AD diagnosed by Patients with evidence of insulin dependent diabetes, mellitus or other endocrine disorders; asthma, obstructive pulmonary disease or clinically significant uncontrolled gastrointestinal, hepatic, or cardiovascular diseases; patients with hypersensitivity to ChE inhibitors or taking TAC within 1 month of Concomitant medications such as anticholinergics, anticonvulsants, antidepressants, and antipsychotics were not allowed;
Drugs Authors: Rogers et al. 44 Setting: Multi-center (20 sites) donepezil 5 mg/d 24 weeks 154 NINCDS guidelines; MMSE score of 10 – 26; CDR score of 1 or 2 baseline were excluded prohibited; all other drugs allowed
Alzheimer Year: 1998 Country: US Eisai Inc. Study design: RCT Sample size: 473
Final Report Update 1 Efficacy/Effectiveness STUDY: FUNDING: RESEARCH OBJECTIVE: DESIGN: INTERVENTION: Dose: Duration: Sample size: INCLUSION: EXCLUSION: OTHER MEDICATIONS/ INTERVENTIONS ALLOWED: Alzheimer's Drugs
